Last reviewed 2026-04-22 · How we verify

DA5221-T2

DA5221-T2 is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss.

DA5221-T2 is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss. Used for Type 2 diabetes mellitus, Obesity or weight management.

At a glance

Mechanism of action

By simultaneously activating GLP-1 and GIP receptors, DA5221-T2 enhances insulin secretion in response to glucose, slows gastric emptying, and increases satiety, leading to improved blood glucose levels and reduced body weight. This dual-agonist approach may provide superior efficacy compared to single GLP-1 agonists in managing type 2 diabetes and obesity.

Approved indications

• Type 2 diabetes mellitus
• Obesity or weight management

Common side effects

• Nausea
• Vomiting
• Diarrhea
• Gastrointestinal disorders

Key clinical trials

• Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.